BMS-986497 (ORM-6151)

Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
35 patients (estimated)
Sponsors
Bristol Myers Squibb
Tags
GSPT1 Degrader, CD33
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1914
NCT Identifier
NCT06419634

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.